Citations

Showing 10 of 108104 citations.

Ultrasound-guided lumbar medial branch blocks and intra-articular facet joint injections: a systematic review and meta-analysis
Ashmore, Zachary , Bies, Michael M. , Hooten, W. Michael , Ashmore, Zachary M, Meiling, James B. , Hassett, Leslie C. , Hunt, Christine L., Hooten, W Michael , Moman, Rajat N. , Hunt, Christine , Cohen, Steven P.

Mayo Clinic

PAIN Reports | May 18, 2022 | Volume: 7 | Issue: 3 | Pages: e1008

10.1097/pr9.0000000000001008 | PMID 35620250 Get It

Abstract There is great interest in expanding the use of ultrasound (US), but new challenges exist with its application to lumbar facet–targeted procedures. The primary aim of this systematic review and meta-analysis was to determine the risk of incorrect needle placement associated with US–guided lumbar medial branch blocks (MBB) and facet joint injections (FJI) as confirmed by fluoroscopy or computerized tomography (CT). An a priori protocol was registered, and a database search was conducted. Inclusion criteria included all study types. Risk of bias was assessed using the Cochrane risk of bias tool for randomized controlled trials and the National Heart, Lung, and Blood tool for assessing risk bias for observational cohort studies. Pooled analysis of the risk difference (RD) of incorrect needle placement was calculated. Pooled analysis of 7 studies demonstrated an 11% RD (P < 0.0009) of incorrect needle placement for US-guided MBB confirmed using fluoroscopy with and without contrast. Pooled analysis of 3 studies demonstrated a 13% RD (P < 0.0001) of incorrect needle placement for US-guided FJI confirmed using CT. The time to complete a single-level MBB ranged from 2.6 to 5.0 minutes. The certainty of evidence was low to very low. Ultrasound-guided lumbar MBB and FJI are associated with a significant risk of incorrect needle placement when confirmed by fluoroscopy or CT. The technical limitations of US and individual patient factors could contribute to the risk of incorrect needle placement.
A Randomized Double-Blinded Placebo Controlled Trial of Clazakizumab for the Treatment of COVID-19 Pneumonia With Hyperinflammation*
Spiegler, Peter, Wesson, Russell , Weldon, Elaina , Dieter, Rebecca A., Quinn, Max M., Mattoo, Aprajita , Soomro, Irfana, Leung, Sherry , Deterville, Cecilia L., Landrum, B. Mark, Ali, Muhammad Imran, Cohen, David J. , Singer, Andrew L., Sen, Ayan , Lonze, Bonnie E. , Alachkar, Nada , Petkova, Eva , Dieter, Rebecca A. , Li, Yi , Cohen, Steven M. , Ali, Muhammad Imran, Chong, Edward, Hochman, Judith S. , Troxel, Andrea B. , Montgomery, Robert A.

Mayo Clinic

Critical Care Medicine | May 18, 2022 | Volume: 50 | Issue: 9 | Pages: 1348-1359

10.1097/ccm.0000000000005591 | PMID 35583232 Get It

OBJECTIVES: We designed this study to test whether clazakizumab, a direct interleukin-6 inhibitor, benefits patients hospitalized with severe or critical COVID-19 disease accompanied by hyperinflammation. DESIGN: Multicenter, randomized, double-blinded, placebo-controlled, seamless phase II/III trial. SETTING: Five U.S. medical centers. PATIENTS: Adults inpatients with severe COVID-19 disease and hyperinflammation. INTERVENTIONS: Eighty-one patients enrolled in phase II, randomized 1:1:1 to low-dose (12.5 mg) or high-dose (25 mg) clazakizumab or placebo. Ninety-seven patients enrolled in phase III, randomized 1:1 to high-dose clazakizumab or placebo. MEASUREMENTS AND MAIN RESULTS: The primary outcome was 28-day ventilator-free survival. Secondary outcomes included overall survival, frequency and duration of intubation, and frequency and duration of ICU admission. Per Data Safety and Monitoring Board recommendations, additional secondary outcomes describing clinical status and status changes, as measured by an ordinal scale, were added. Bayesian cumulative proportional odds, logistic, and Poisson regression models were used. The low-dose arm was dropped when the phase II study suggested superiority of the high-dose arm. We report on 152 patients, 74 randomized to placebo and 78 to high-dose clazakizumab. Patients receiving clazakizumab had greater odds of 28-day ventilator-free survival (odds ratio [OR] = 3.84; p [OR > 1] 99.9%), as well as overall survival at 28 and 60 days (OR = 1.75; p [OR > 1] 86.5% and OR = 2.53; p [OR > 1] 97.7%). Clazakizumab was associated with lower odds of intubation (OR = 0.2; p [OR] < 1; 99.9%) and ICU admission (OR = 0.26; p [OR < 1] 99.6%); shorter durations of ventilation and ICU stay (risk ratio [RR] < 0.75; p [RR < 1] > 99% for both); and greater odds of improved clinical status at 14, 28, and 60 days (OR = 2.32, p [OR > 1] 98.1%; OR = 3.36, p [OR > 1] 99.6%; and OR = 3.52, p [OR > 1] 99.8%, respectively). CONCLUSIONS: Clazakizumab significantly improved 28-day ventilator-free survival, 28- and 60-day overall survival, as well as clinical outcomes in hospitalized patients with COVID-19 and hyperinflammation.
Peripartum Cardiomyopathy and Associated Arrhythmias: A Contemporary Review
Ibrahim, Ramzi , William, Preethi , Ibrahim, Ramzi , Lee, Justin

Mayo Clinic

No container title available | May 18, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.165286624.47939101/v1 Get It

Peripartum cardiomyopathy is an idiopathic cardiomyopathy that most commonly affects women in the third trimester of pregnancy or in the first five months of the postpartum period. Peripartum cardiomyopathy is associated with a myriad of different findings on electrocardiograms. There is also a risk of supraventricular tachycardia, atrial fibrillation, atrial flutter, and ventricular arrhythmias. This review discusses the prevalence and management of tachyarrhythmias and bradyarrhythmias in peripartum cardiomyopathy.
Cardiovascular/Stroke Risk Assessment in Patients with Erectile Dysfunction—A Role of Carotid Wall Arterial Imaging and Plaque Tissue Characterization Using Artificial Intelligence Paradigm: A Narrative Review
Khanna, Narendra N. , Maindarkar, Mahesh , Saxena, Ajit Kumar , Ahluwalia, Puneet , Paul, Sudip , Srivastava, Saurabh Kumar , Cuadrado‐Godia, Elisa , Omerzu, Tomaž , Saba, Luca , Mavrogeni, Sophie , Turk, Monika, Laird, John R. , Fatemi, Mostafa , Barqawi, Al B. , Miner, Martin , Singh, Inder M. , Johri, Amer M. , Kalra, Mannudeep, Agarwal, Vikas , Paraskevas, Kosmas I. , Teji, Jagjit S. , Fouda, Mostafa M. , Pareek, Gyan , Suri, Jasjit S. , Mavrogeni, Sophie , Fatemi, Mostafa , Agarwal, Vikas , Paraskevas, Kosmas I , Fouda, Mostafa M , Paul, Sudip , Maindarkar, Mahesh A , Sharma, Aditya , Kitas, George D. , Suri, Jasjit S.

Mayo Clinic

Diagnostics | May 18, 2022 | Volume: 12 | Issue: 5 | Pages: 1249

10.3390/diagnostics12051249 | PMID 35626404 Get It

Purpose: The role of erectile dysfunction (ED) has recently shown an association with the risk of stroke and coronary heart disease (CHD) via the atherosclerotic pathway. Cardiovascular disease (CVD)/stroke risk has been widely understood with the help of carotid artery disease (CTAD), a surrogate biomarker for CHD. The proposed study emphasizes artificial intelligence-based frameworks such as machine learning (ML) and deep learning (DL) that can accurately predict the severity of CVD/stroke risk using carotid wall arterial imaging in ED patients. Methods: Using the PRISMA model, 231 of the best studies were selected. The proposed study mainly consists of two components: (i) the pathophysiology of ED and its link with coronary artery disease (COAD) and CHD in the ED framework and (ii) the ultrasonic-image morphological changes in the carotid arterial walls by quantifying the wall parameters and the characterization of the wall tissue by adapting the ML/DL-based methods, both for the prediction of the severity of CVD risk. The proposed study analyzes the hypothesis that ML/DL can lead to an accurate and early diagnosis of the CVD/stroke risk in ED patients. Our finding suggests that the routine ED patient practice can be amended for ML/DL-based CVD/stroke risk assessment using carotid wall arterial imaging leading to fast, reliable, and accurate CVD/stroke risk stratification. Summary: We conclude that ML and DL methods are very powerful tools for the characterization of CVD/stroke in patients with varying ED conditions. We anticipate a rapid growth of these tools for early and better CVD/stroke risk management in ED patients.
Functional implications of microvascular heterogeneity for oxygen uptake and utilization
Roy, Tuhin K. , Secomb, Timothy W. , Roy, Tuhin K , Secomb, Timothy W

Mayo Clinic

Physiological Reports | May 18, 2022 | Volume: 10 | Issue: 10 | Pages: No page available

10.14814/phy2.15303 | PMID 35581743 Get It

Abstract In the vascular system, an extensive network structure provides convective and diffusive transport of oxygen to tissue. In the microcirculation, parameters describing network structure, blood flow, and oxygen transport are highly heterogeneous. This heterogeneity can strongly affect oxygen supply and organ function, including reduced oxygen uptake in the lung and decreased oxygen delivery to tissue. The causes of heterogeneity can be classified as extrinsic or intrinsic. Extrinsic heterogeneity refers to variations in oxygen demand in the systemic circulation or oxygen supply in the lungs. Intrinsic heterogeneity refers to structural heterogeneity due to stochastic growth of blood vessels and variability in flow pathways due to geometric constraints, and resulting variations in blood flow and hematocrit. Mechanisms have evolved to compensate for heterogeneity and thereby improve oxygen uptake in the lung and delivery to tissue. These mechanisms, which involve long‐term structural adaptation and short‐term flow regulation, depend on upstream responses conducted along vessel walls, and work to redistribute flow and maintain blood and tissue oxygenation. Mathematically, the variance of a functional quantity such as oxygen delivery that depends on two or more heterogeneous variables can be reduced if one of the underlying variables is controlled by an appropriate compensatory mechanism. Ineffective regulatory mechanisms can result in poor oxygen delivery even in the presence of adequate overall tissue perfusion. Restoration of endothelial function, and specifically conducted responses, should be considered when addressing tissue hypoxemia and organ failure in clinical settings.
Autosomal dominant and sporadic late onset Alzheimer's disease share a commonin vivopathophysiology
Schofield, Peter R. , Weiner, Michael W. , Xiong, Chengjie , Coble, Dean W. , Saito, Naomi , Aisen, Paul, Berman, Sarah , Cairns, Nigel J., Carrillo, María C. , Chui, Helena C., Chhatwal, Jasmeer P. , Fagan, Anne M. , Farlow, Martin R. , Fox, Nick C. , Goate, Alison , Gordon, Brian A. , Graff‐Radford, Neill R. , Day, Gregory S. , Hassenstab, Jason , Jack, Clifford R. , Jagust, William J. , Massoumzadeh, Parinaz , Masters, Colin L. , Mori, Hiroshi , Noble, James M. , Petersen, Ronald C. , Ringman, John M. , Salloway, Stephen , Saykin, Andrew J. , Shaw, Leslie M. , Trojanowski, John Q. , Vöglein, Jonathan , Weninger, Stacie, Bateman, Randall J. , Buckles, Virginia, Morris, John C. , Schofield, Peter R , Gordon, Brian A , Ikeuchi, T , Jack, Clifford R , Jagust, William J , Masters, Colin L , Vöglein, Jonathan , Saykin, Andrew J , Day, Gregory S , Bateman, Randall J , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Goate, Alison M , Berman, Sarah , Noble, James M , Xiong, Chengjie , Beckett, Laurel , Allegri, Ricardo , Benzinger, Tammie L.S. , Chui, Helena C. , Cruchaga, Carlos , Ghetti, Bernardino , Ikeuchi, Takeshi , Jucker, Mathias , Martins, Ralph N. , McDade, Eric , Toga, Arthur W.

Mayo Clinic

Brain | May 17, 2022 | Volume: 145 | Issue: 10 | Pages: 3594-3607

10.1093/brain/awac181 | PMID 35580594 Get It

AbstractThe extent to which the pathophysiology of autosomal dominant Alzheimer's disease corresponds to the pathophysiology of ‘sporadic’ late onset Alzheimer's disease is unknown, thus limiting the extrapolation of study findings and clinical trial results in autosomal dominant Alzheimer's disease to late onset Alzheimer's disease.We compared brain MRI and amyloid PET data, as well as CSF concentrations of amyloid-β42, amyloid-β40, tau and tau phosphorylated at position 181, in 292 carriers of pathogenic variants for Alzheimer's disease from the Dominantly Inherited Alzheimer Network, with corresponding data from 559 participants from the Alzheimer’s Disease Neuroimaging Initiative. Imaging data and CSF samples were reprocessed as appropriate to guarantee uniform pipelines and assays. Data analyses yielded rates of change before and after symptomatic onset of Alzheimer's disease, allowing the alignment of the ∼30-year age difference between the cohorts on a clinically meaningful anchor point, namely the participant age at symptomatic onset.Biomarker profiles were similar for both autosomal dominant Alzheimer's disease and late onset Alzheimer's disease. Both groups demonstrated accelerated rates of decline in cognitive performance and in regional brain volume loss after symptomatic onset. Although amyloid burden accumulation as determined by PET was greater after symptomatic onset in autosomal dominant Alzheimer's disease than in late onset Alzheimer's disease participants, CSF assays of amyloid-β42, amyloid-β40, tau and p-tau181 were largely overlapping in both groups. Rates of change in cognitive performance and hippocampal volume loss after symptomatic onset were more aggressive for autosomal dominant Alzheimer's disease participants.These findings suggest a similar pathophysiology of autosomal dominant Alzheimer's disease and late onset Alzheimer's disease, supporting a shared pathobiological construct.
Bringing context and nuance to risk prediction by incorporating social determinants of health
Yao, Xiaoxi , Noseworthy, Peter A.

Mayo Clinic

European Journal of Preventive Cardiology | May 17, 2022 | Volume: 29 | Issue: 10 | Pages: 1463-1464

10.1093/eurjpc/zwac098 | PMID 35580587 Get It

Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care
Sidana, Surbhi , Allmer, Cristine, Dueck, Amylou C. , Yost, Kathleen J. , Warsame, Rahma , Thanarajasingam, Gita , Cerhan, James R. , Nowakowski, Grzegorz S. , Lin, Yi , Ansell, Stephen M. , Thompson, Carrie A. , Kumar, Shaji , Dueck, A. C. , Yost, Kathleen , Warsame, Rahma , Cerhan, James R , Paludo, Jonas , Nowakowski, Grzegorz S , Lin, Yi , Gertz, Morie A , Witzig, T.E. , Dispenzieri, Angela , Ansell, Stephen M , Thompson, Carrie A , Kumar, Shaji K , Sidana, Surbhi , Larson, Melissa C. , Paludo, Jonas , Rajkumar, S. Vincent , Habermann, Thomas M. , Gertz, Morie A. , Witzig, Thomas E. , Dispenzieri, Angela , Gonsalves, Wilson I.

Mayo Clinic

JCO Oncology Practice | May 17, 2022 | Volume: 18 | Issue: 8 | Pages: e1320-e1333

10.1200/op.21.00789 | PMID 35580285 Get It

PURPOSE: Patients' concerns regarding clinical trial (CT) participation include apprehension about side effects, quality of life (QoL), financial burden, and quality of care. METHODS: We prospectively evaluated the experience of patients with multiple myeloma or lymphoma who were treated on CTs (CT group, n = 35) versus patients treated with standard approaches (non-CT group, n = 88) focusing on QoL, financial burden of care, and patients' perception of quality of care over a 1-year period. RESULTS: There were no significant differences in any of the patient-reported outcomes in CT versus non-CT groups. We observed an initial decline in overall QoL in the first 3 months across both groups, driven primarily by physical and functional well-being. QoL gradually improved and was above baseline by month 12. Patients reported highest improvement in the functional well-being subdomain. Patients in both groups reported high satisfaction with the quality of care received, and there were no differences in overall satisfaction, communication with team, or access to care. At baseline, 16%-19% of patients reported financial burden, which increased to a peak of 33% in the CT group and to 49% in the non-CT group over the course of 1 year. There was no significant difference in financial burden in the two groups overall. Most of the patients reported getting all the care that was deemed medically necessary in both groups. However, a significant proportion of patients reported having to make other kinds of financial sacrifices because of their cancer (CT group: 33% of patients at baseline and 21%-40% over 1 year; non-CT group: 19% at baseline and 25%-36% over 1 year). CONCLUSION: Patients treated on CTs reported comparable QoL and quality of care with the non-CT group. A high proportion of patients reported financial burden over time in both groups. Our findings can serve as a guide to educate patients regarding CT participation and highlight the need to address the significant financial burden experienced by patients with cancer.
Pulmonary Congestion During Exercise Stress Echocardiography in Ischemic and Heart Failure Patients
Merli, Elisa , Scali, Maria Chiara, Zagatina, A , Merlo, Pablo , Daros, Clarissa Borguezan , Pretto, José Luis de Castro e Silva , Amor, Miguel , Salamè, Michael, Mosto, Hugo , Reisenhofer, Barbara, Wierzbowska‐Drabik, Karina , Kasprzak, Jarosław D. , Ágoston, Gergely , Varga, Albert , Dodi, Claudio , Cortigiani, Lauro , Simova, Iana , Samardjieva, Martina, Citro, Rodolfo , Čelutkienė, Jelena , Re, Federica , Gligorova, Suzana , Antonini‐Canterin, Francesco, Carpeggiani, Clara , Picano, Eugenio , (SIECVI), on behalf of Stress Echo 2020 and 2030 study group of the Italian Society of Echocardiography and Cardiovascular Imaging, Zagatina, Angela , Merlo, Pablo Martin , Borguezan-Daros, Clarissa , de Castro E Silva Pretto, José Luis , Amor, Miguel , Mosto, Hugo , Morrone, Doralisa , Rodriguez-Zanella, Hugo , Kasprzak, Jaroslaw D , Simova, Iana , Citro, Rodolfo , Monte, Ines , Gligorova, Suzana , Pellikka, Patricia A , Wierzbowska-Drabik, Karina , Celutkiene, Jelena , Ciampi, Quirino , Arbucci, Rosina , Morrone, Doralisa , D’Andrea, Antonello , Rodríguez‐Zanella, Hugo , Lowenstein, Jorge , Monte, Ines , Pepi, Mauro , Pellikka, Patricia A. , (SIECVI), on behalf of Stress Echo 2020 and 2030 study group of the Italian Society of Echocardiography and Cardiovascular Imaging

Mayo Clinic

Circulation: Cardiovascular Imaging | May 17, 2022 | Volume: 15 | Issue: 5 | Pages: No page available

10.1161/circimaging.121.013558 | PMID 35580160 Get It

Background: Lung ultrasound detects pulmonary congestion as B-lines at rest, and more frequently, during exercise stress echocardiography (ESE). Methods: We performed ESE plus lung ultrasound (4-site simplified scan) in 4392 subjects referred for semi-supine bike ESE in 24 certified centers in 9 countries. B-line score ranged from 0 (normal) to 40 (severely abnormal). Five different populations were evaluated: control subjects (n=103); chronic coronary syndromes (n=3701); heart failure with reduced ejection fraction (n=395); heart failure with preserved ejection fraction (n=70); ischemic mitral regurgitation ≥ moderate at rest (n=123). In a subset of 2478 patients, follow-up information was available. Results: During ESE, B-lines increased in all study groups except controls. Age, hypertension, abnormal ejection fraction, peak wall motion score index, and abnormal heart rate reserve were associated with B-lines in multivariable regression analysis. Stress B lines (hazard ratio, 2.179 [95% CI, 1.015–4.680]; P =0.046) and ejection fraction <50% (hazard ratio, 2.942 [95% CI, 1.268–6.822]; P =0.012) were independent predictors of all-cause death (n=29 after a median follow-up of 29 months). Conclusions: B-lines identify the pulmonary congestion phenotype at rest, and more frequently, during ESE in ischemic and heart failure patients. Stress B-lines may help to refine risk stratification in these patients. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT 03049995.
Acquired peripheral nerve injuries associated with severe COVID-19
Franz, Colin K. , Murthy, Nikhil K. , Malik, George R. , D’Andrea, Dom, Wolfe, Alexis R. , Stearns, Melanie , Deshmukh, Swati , Tavee, Jinny , Sun, Fang , Swong, Kevin , Rydberg, Leslie , Wolfe, Lisa F. , Rogers, John A. , Franz, Colin K , Kwak, Jean Won , Farr, Ellen , Cotton, Ronald James , Walter, James McCauley , Coleman, John M.

Mayo Clinic

No container title available | May 17, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1623741/v1 Get It

Abstract We diagnosed 66 peripheral nerve injuries in 34 patients who survived severe coronavirus disease 2019 (COVID-19). We combine our latest data with published case series re-analyzed here (117 nerve injuries; 58 patients) to provide a comprehensive accounting of lesion sites. The most common are ulnar (25.1%), common fibular (15.8%), sciatic (13.1%), median (9.8%), brachial plexus (8.7%) and radial (8.2%) nerves at sites known to be vulnerable to mechanical loading. Protection of peripheral nerves should be prioritized in the care of COVID-19 patients. To this end, we report proof of concept data of a wearable, wireless pressure sensor to provide real time monitoring in the intensive care unit setting.